BioCentury | Oct 5, 2018
Company News

Roche gains CD25 program via Tusk takeout

...IL-2’s function on effector T cells (see "Tusk's Take on CD25" ). Newly formed spinout Black Belt Therapeutics Ltd....
...Generic), Tecentriq (Other), Anti-PDL1 (Other) Droia Oncology Ventures Genentech Inc. Tusk Therapeutics Ltd. Roche CD38 Interleukin-2 (IL-2) Interleukin-2 (IL-2) receptor alpha chain (CD25) Black Belt Therapeutics Ltd....
Items per page:
1 - 1 of 1
BioCentury | Oct 5, 2018
Company News

Roche gains CD25 program via Tusk takeout

...IL-2’s function on effector T cells (see "Tusk's Take on CD25" ). Newly formed spinout Black Belt Therapeutics Ltd....
...Generic), Tecentriq (Other), Anti-PDL1 (Other) Droia Oncology Ventures Genentech Inc. Tusk Therapeutics Ltd. Roche CD38 Interleukin-2 (IL-2) Interleukin-2 (IL-2) receptor alpha chain (CD25) Black Belt Therapeutics Ltd....
Items per page:
1 - 1 of 1